Conexeu Sciences Inc. - What You Need to Know

Thinking about investing in Conexeu Sciences? It is exciting to get in early, but let’s look at what this company actually does before you invest your money.

1. What does this company do?

Conexeu is an early-stage medical device company. They are developing CXU™, a collagen-based "scaffold" for wound healing. Think of it as a liquid bandage: once applied, it turns into a gel that helps the body repair itself.

Important note: This product is still in the "preclinical" phase. It has not been tested on humans or approved by the FDA. The company is essentially a research project trying to become a business. They also hope to use this technology for cosmetic fillers, but that remains unproven. Currently, the company makes no money from sales because CXU™ is still in development.

2. Is this a typical IPO?

No. This is a "direct listing," not a traditional IPO. In a normal IPO, an investment bank sets the price and helps manage the stock. Here, Conexeu is simply listing existing shares on the Nasdaq (ticker: CNXU) for public trading. Because no bank is managing the process, the stock price may be more volatile when it starts trading on May 21, 2026. There is no safety net to support the price if it drops on the first day.

3. Who is selling these shares?

The company is not selling new shares to raise cash. This listing is for current shareholders—people who own shares from past private deals—who want to sell them to you. If you buy, you are buying from these existing owners, not the company.

Warning: There is no "lock-up" period. Early investors, directors, and officers can sell their shares immediately. If many sell at once, the stock price could drop quickly. Since the company is not issuing new shares, it receives no money from these sales.

4. What are the main risks?

• It’s Unproven: They have zero sales and have lost money every year since 2022. Their future depends entirely on one product that lacks FDA approval. They rely heavily on outside funding to keep the lights on.
• Legal & Safety Risks: If the product is approved, the company faces major risks if it causes injury or is used incorrectly. Lawsuits or recalls could quickly drain their limited cash. The company didn't provide much detail about their insurance coverage in their filing, which is something to keep in mind.
• Tough Competition: They are entering a crowded market against massive, well-funded companies. These competitors have better brand recognition and more money for clinical trials.
• Economic Sensitivity: If the economy struggles, people spend less on cosmetic procedures. This would hurt the company’s potential revenue from fillers.

5. The Bottom Line

Only invest if you can afford to lose your entire investment. This is a high-stakes bet on a company with no revenue, unproven products, and significant regulatory hurdles.

Before you hit "buy": Always read the official "Prospectus" available on the SEC website. It contains the full legal details that this summary might miss. If you aren't sure if this fits your risk tolerance, it is always a good idea to chat with a financial advisor first.